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doi:10.1016/j.ejvs.2008.08.018Abstract Objectives: To investigate the presence of lower limb deep vein thrombosis (DVT)
and prognosis in patients with symptomatic pulmonary embolism (PE).
Materials and methods: A total of 203 consecutive referral patients with PE were included.
The distribution of DVT was evaluated with compression ultrasound (CUS), and all patients
were then followed for 12 months for investigation of recurrence of venous thromboembolism
(VTE) and fatal events as adverse outcome.
Results: The mean age of the patients was 62.8 years, and 78 (38.4%) were males. DVT was
found in 118 (58.1%) patients. Of these patients, 61 (30.0%) had proximal DVT. Multivariate
analysis demonstrated that active cancer, inadequate anticoagulation, leg symptoms, male
gender, presence of DVT, presence of proximal DVT, and previous DVT were independent risk
factors for adverse outcome. A clinical risk score ranging from 0 to 10 points was generated on
the basis of multivariate regression coefficients. Receiver operating characteristic curve anal-
ysis showed that an appropriate cut-off point for discriminating between the presence and the
absence of an adverse event was 4. Using this category, 166 (81.8%) patients were classified as
low risk and 37 (18.2%) as high risk for adverse outcome. The adverse event rates were 6.0% for
the low-risk group and 59.5% for the high-risk group.
Conclusions: This study has confirmed the clinical significance of surveillance CUS in patients
with a first episode of PE. Furthermore, a simple risk score on the basis of available variables
can identify patients at risk of an adverse outcome in patients with PE.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.3353 8111; fax: þ81 3 3225 0940.
u.ac.jp, Yamakit@aol.com (T. Yamaki).
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Deep vein thrombosis (DVT) is associated with acute
symptoms of lower extremity including pain, swelling,
symptomatic pulmonary embolism (PE), heart failure, and
death in some cases. In recent years, DVT and PE have been
increasingly considered as a single disease, namely venous
thromboembolism (VTE).1 Indeed, an asymptomatic
pulmonary embolism can be found in about half of patients
presenting with symptomatic proximal deep vein throm-
bosis.2 Moreover, DVT and PE share many risk factors
including age, immobilization, major surgery or trauma,
active cancer, pregnancy, oral contraceptive use, and
hormone replacement therapy.
VTE is a potentially life-threatening disease with
>200,000 first lifetime cases reported each year in the
United States,3 and fatalities in the United States from
pulmonary embolism are estimated at 100,000e200,000
persons per year.4 Therefore, the clinical challenge has
been directed toward identifying patients at risk of PE to
reduce the morbidity and mortality of the disease process.
Many patients who develop VTE have well-recognized
risk factors that are associated with this condition.5e7
However, the exact prevalence of residual DVT in patients
with acute PE is not known, and presence of DVT as a cause
of clinically important PE has been debated.8e10 Moreover,
little is known on the outcome of VTE between PE patients
with DVT and those without. To evaluate outcome after
development of PE, a simple risk score on the basis of easily
available variables can accurately identify patients at risk
of an adverse outcome.11 Therefore, this study was
undertaken to investigate the clinical significance of
surveillance CUS of the lower extremities and analysis of
risk factors in patients with symptomatic PE. We have
devised a risk score using methods described by Wicki et al.




Between February 2002 and May 2007, a total of 215
consecutive referral patients with confirmed cardiopulmo-
nary stable PE were prospectively evaluated using bilateral
lower extremity CUS. The initial management of all
patients with proven PE was performed in the pulmonary or
cardiovascular unit, and follow-up was performed at the
Department of Plastic and Reconstructive Surgery. Basi-
cally, the treatment consisted of intravenous unfractio-
nated heparin for 5e14 days during the acute phase
adjusted to maintain the activated partial thromboplastin
time (APTT) at 1.5e2.5 times control,12 followed by oral
warfarin for at least 6 months. The international normal-
ized ratio (INR) level of 2e3 was considered to be a suffi-
cient therapeutic range. However, precise data on the
duration of outpatient anticoagulation therapy were not
collected. The patients were followed for 12 months for
investigation of recurrence of VTE and fatal PE. The pres-
ence of leg symptoms at initial presentation, including
swelling, pain, and erythema was recorded.The patients’ risk factors for VTE, including active
cancer, congestive heart disease, hormone replacement
therapy, immobilization, inadequate INR level, inflamma-
tory bowel disease, known thrombophilia, operation and
trauma, previous DVT and renal failure were all evaluated.
The thrombophilia screen in this study included protein C,
protein S, antithrombin III, antiphospholipid antibody,
homocysteine and plasminogen level. Factor V Leiden and
Prothrombin G20210A were excluded from the study
because the 215 study patients were all Japanese. Exclu-
sion criteria from the study included: (1) lower extremity
symptoms lasting 1 month, (2) cardiopulmonary unstable
PE with massive pulmonary embolism; (3) life expect-
ancy< 3 months, (4) therapeutic dose anticoagulation
instituted for >48 h before examination and (5) loss to
follow-up.
Compression ultrasound
The presence of DVT was diagnosed with compression
ultrasound by one experienced physician (TY). A colour
duplex ultrasound system (LOGIQ 7 PRO: GE Yokogawa
Medical Systems, Tokyo, Japan) with a 5e10 MHz trans-
ducer was used. Initially, each patient was placed supine in
a reverse Trendelenburg position with the knee flexed at 15
degrees. The examination began at the common femoral
vein (CFV), and moved to the femoral vein (FV) at the
adductor canal. The anterior and posterior tibial veins (ATV
and PTV) were also recorded. Afterwards, the patient was
placed prone with the knee flexed at 30 degrees, and the
residual popliteal (POPV), peroneal (PV), gastrocnemius
(GV) and soleal veins (SV) were evaluated.13 Thrombosis
was considered proximal if it involved the deep veins in
CFV, FV and POPV with or without calf vein thrombosis.
Thrombosis was considered distal if it involved only the calf
veins.
Follow-up
All patients were followed up for 12 months after the
initial episode of PE. In the cohort study, the follow-up
protocol was outpatient clinic visit at 2 weeks, 1 and 3
months and every 3 months. Clinically important adverse
events recorded during 12-month follow-up were symp-
tomatic VTE and fatal events. Recurrent nonfatal PE was
defined as a new perfusion/ventilation mismatch on lung
scan and/or a new intraluminal filling defect on spiral CT
of the chest in patients who had suspected PE symptoms
including dyspnoea, chest pain and syncope. Both definite
and probable fatal PE (sudden death of undetermined
cause) were considered as fatal PE. CUS of the lower
extremities was performed at each visit, and recurrent
DVT was defined as a new incompressible segment of the
vein on B-mode, and no spontaneous flow on colour
Doppler imaging.
Statistical analysis
All data were analysed using StatView for Windows (Version
5.0, SAS Institute Inc., Cary, NC). The chi-squared test was
used to evaluate differences between proportions. To
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symptomatic recurrent VTE, potential confounding vari-
ables were chosen using univariate analysis (p< 0.10). And
final odds ratio (OR) and 95% confidence intervals (CI) were
calculated using multiple logistic regression analysis.
Continuous data were expressed as mean standard devi-
ation (SD). Statistical significance was defined as p< 0.05.
Risk score
To generate a simple risk score using the result of the
multivariate logistic regression analysis, positive points
were assigned in proportion to the regression coefficients.
The individual risk scores were calculated, and the optimal
cut-off point for discriminating between a low risk and
a high risk of adverse outcome was determined using
receiver operating characteristic (ROC) curve analysis
(MedCalc software, Mariakerke, Belgium).
Results
Patients
Table 1 shows the baseline characteristics of the study
patients. Of the 215 consecutive patients evaluated, 12
were excluded on the basis of the criteria described
previously. Thus, 203 patients were eligible for the study.




Number of patients eligible 203
Mean age (y) 62.8 15.9
Male gender (%) 78 (38.4)
Inpatients (%) 175 (86.2)
Leg symptoms (%) 83 (40.9)
Number of patients with DVT (%) 118 (58.1)
Number of patients with proximal DVT (%) 61 (30.0)
Risk factors (%)
Active cancer 30 (14.8)
Congestive heart failure 26 (12.8)
Hormone replacement therapy 18 (8.9)
Immobilization 35 (17.2)
Inadequate anticoagulation 33 (16.3)
Inflammatory bowel disease 4 (2.0)
Operation and trauma 69 (34.0)
Previous history of DVT 18 (8.9)
Renal failure 15 (7.4)
Thrombophilia 14 (6.9)
Protein C deficiency 1 (0.5)
Protein S deficiency 5 (2.5)
Antithrombin III deficiency 4 (2.0)
Positive antiphospholipid syndrome 3 (1.5)
Hyperhomocysteinemia 0 (0)
Abnormal plasminogen 1 (0.5)and 78 (38.4%) were males. Leg symptoms were found in 83
(40.9%) patients. In this study, operation and trauma were
the most common risk factors for PE (69 patients, 34.0%),
followed by immobilization (35 patients, 17.2%), inade-
quate anticoagulation (33 patients, 16.3%), active cancer
(30 patients, 14.8%), congestive heart failure (26 patients,
12.8%), hormone replacement therapy (18 patients, 8.9%),
previous history of DVT (18 patients, 8.9%), and known
thrombophilia (14 patients, 6.9%). Of the 203 patients
evaluated, DVT was found in 118 (58.1%), and proximal DVT
was detected in 61 (30.0%) patients.
Evaluation of initial DVT
Table 2 shows the distribution of DVT in patients who had
PE and DVT at initial examination. Sixty-one patients
(30.0%) had proximal DVT, and the remaining 57 (28.1%)
had distal DVT; no significant difference was found in the
distribution of DVT (pZ 0.662). There were 50 (24.6%)
patients with isolated venous segment DVT and 68
(33.5%) with multisegment DVT. In the isolated venous
segment, distal veins had a significantly higher propor-
tion of DVT compared to proximal veins (p< 0.0001).
Similarly, a significantly higher proportion of proximal
DVT was found in patients with multisegment DVT
(p< 0.0001).
Fig. 1 shows the detailed anatomic distribution of DVT.
Clot burden segment was most frequently found in the SV
(66.1%), followed by POPV, PV, FV, CFV, and GV (38.1%,
35.6%, 26.3%, 23.7% and 20.3%, respectively). In contrast,
thrombi were less frequently found in the PTV, ATV, and
DFV (7.6%, 8.5% and 9.3%, respectively).
Clinical outcome
Adverse events were encountered in 32 (15.8%) patients
(Table 3). Of these, recurrent VTE during 12-month follow-
up was found in 14 (6.9%) patients. Four patients (2.0%) had
recurrent PE, 5 (2.5%) had recurrent DVT, and 3 (1.5%) had
recurrent PE and DVT. There was a significant difference inTable 2 Distribution of deep vein thrombosis in patients
with deep vein thrombosis and pulmonary embolism
Distribution of DVT nZ 203
patients (%)
P-value
Proximal DVT 61 (30.0)
Distal DVT 57 (28.1) 0.662
Total 118 (58.1)
Isolated segment
Proximal DVT 9 (4.4)
Distal DVT 41 (20.2) <0.0001
Total 50 (24.6)
Multisegment
Proximal DVT 52 (25.6)
Distal DVT 16 (7.9) <0.0001
Total 68 (33.5)
DVT: deep vein thrombosis, and PE: pulmonary embolism.
Fig. 1 Detailed anatomic distribution of initial deep vein thrombosis. CFV: common femoral vein, FV: femoral vein, DFV: deep
femoral vein, POPV: popliteal vein, ATV: anterior tibial vein, PTV: posterior tibial vein, PV: peroneal vein, GV: gastrocnemius vein,
and SV: soleal vein.
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without DVT (10.2%, 2.4%, pZ 0.030, respectively). In
patients with PE and DVT, all recurrent events were found
in patients who had proximal DVT. Fatal events were
observed in 23 (11.3%) patients, and there was a signifi-
cantly higher mortality rate in patients who had PE and DVT
(16.1%, 4.7%, pZ 0.012, respectively). Fatal PE events
were found in 5 (2.5%) patients. Of these, 4 (3.4%) patients
initially had PE and DVT, and residual 1 (1.2%) had PE alone.
There was no significant difference in the risk of fatal PE
during 12-month follow-up between patients with DVT and
those without (pZ 0.316).
Risk factors for adverse outcome
The initial risk factors were tested by univariate analysis
(Table 4). Of these, seven potential risk factors were
selected. Multivariate analysis finally demonstrated that
active cancer (OR: 5.54, 95% CI: 2.36e13.0, p< 0.0001),
inadequate anticoagulation (OR: 3.84, 95% CI: 1.66e8.9,
pZ 0.002), leg symptoms (OR: 3.7, 95% CI: 1.69e8.11,
pZ 0.001), male gender (OR: 10.5, 95% CI: 4.1e26.9,
p< 0.0001), presence of DVT (OR: 4.97, 95% CI: 1.84e
13.46, pZ 0.002), presence of proximal DVT (OR: 3.71, 95%
CI: 1.74e7.94, pZ 0.001), and previous history of DVT (OR:
8.39, 95% CI: 3.01e23.35, p< 0.0001) were independent
risk factors for adverse outcome.Table 3 Twelve-month risk of recurrent VTE and fatal events i
Variables PE and DVT
(nZ 118 patients) (%
Recurrent VTE events 12 (10.2)
PE and proximal DVT 8 (6.8)
PE and distal DVT 0 (0)
Recurrent PE 4 (3.4)
Recurrent DVT 5 (4.2)
Recurrent PE and DVT 3 (2.5)
Fatal events 19 (16.1)
Fatal PE 4 (3.4)Risk factors for adverse outcome
A clinical risk score ranging from 0 to 10 points was devised
on the basis of multivariate regression coefficients
(Table 5). ROC curve analysis (Fig. 2) showed that an
appropriate cut-off point for discrimination between the
presence and absence of an adverse event was 4 (sensi-
tivity: 68.7%; specificity: 91.2%) with an area under the ROC
curve of 0.84 (95% CI: 0.78e0.89, pZ 0.0001). After
calculating individual risk scores, patients were then
stratified into low-risk (4) and high-risk (5) groups. Using
this category, 166 (81.8%) patients were classified as having
low and 37 (18.2%) as having high risk for adverse outcome.
The proportion of patients with adverse outcome increased
as the risk score increased (Table 6). The adverse event
rates were 6.0% for the low-risk group and 59.5% for the
high-risk group.
Discussion
In recent years, DVT and PE have increasingly been
considered as a single disease entity, and it is well
recognized that 90% of asymptomatic PE arises from
thrombi in the leg veins.14,15 However, little is known
about the prevalence of concomitant DVT in patients with
PE. In previous reports, the prevalence of detectable DVT











Table 4 Univariate analysis of potential risk factors for
adverse outcome






>70 72 15 0.227
70 131 17
Gender
Male 78 18 <0.0001
Female 125 14
Leg symptoms
Yes 83 22 0.001
No 120 10
Presence of DVT
Yes 118 27 <0.0001
No 85 5
Presence of proximal DVT
Yes 61 21 0.0007
No 142 11
Active cancer
Yes 30 12 0.0001
No 173 20
Congestive heart failure
Yes 26 3 0.427
No 177 29
Hormone replacement therapy
Yes 18 4 0.529
No 185 28
Immobilization
Yes 35 9 0.113
No 168 23
Inadequate INR level
Yes 33 13 0.002
No 170 19
Inflammatory bowel disease
Yes 4 2 0.121
No 199 30
Status
Inpatient 175 28 0.541
Outpatient 28 4
Known thrombophilia
Yes 14 1 0.229
No 189 31
Operation and trauma
Yes 69 13 0.570
No 134 19
Previous history of DVT
Yes 18 7 <0.0001
No 185 25
Renal failure
Yes 15 3 0.638
No 188 29
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studies using different methodologies.16e22 Furthermore,
the prevalence of proximal DVT has varied greatly among
the studies. Girard et al., using CUS, reported that the
prevalence of DVT in PE patients was 60% with an inci-
dence of proximal DVT of 45%.21 Our previous study also
showed that 63% of these patients had DVT, but we found
that the proportion of proximal DVT was similar to that of
distal DVT.22 There are three main factors that may be
responsible for the difference between the prevalence
rates.21 First, CUS has a sensitivity of 96% compared with
venography for proximal DVT with a specificity of 95%.23
Although the specificity is maintained at 90e95% in
symptomatic patients, the sensitivity and specificity
decrease to 70% for distal DVT.23 Second, most pelvic veins
cannot be visualized by CUS. Finally, some of these studies
excluded the screening of calf muscle veins, including the
GV and SV.
Several investigators have reported the important role
of lower extremity CUS in the follow-up of PE. Patients who
suffer a recurrent episode of pulmonary embolism might
first redevelop proximal deep venous thrombosis, and
performance of serial CUS over 2 weeks may identify
patients who are progressing toward recurrent pulmonary
embolism, thus allowing preventive treatment.24,25 With
this management approach, about 2% of patients have
abnormal findings in the proximal deep veins during serial
testing.26
On the other hand, there is still much debate con-
cerning the importance of DVT as a substantial risk factor
in the subsequent development of PE.8e10 Gottlieb et al.
found that only 1.1% of patients had adverse outcomes,
and that adverse outcomes occurred only in postsurgical
patients and were not related to the presence or absence
of calf DVT, or the method of treatment. They concluded
that CUS of the calf is not mandatory at initial evaluation
to identify patients at risk of clinically significant PE.9
Even in the proximal veins, Girard et al. found no signifi-
cant difference in the 3-month risk of recurrent throm-
boembolic event or death among PE patients with and
without DVT.21 In contrast, Seinturier et al. supported the
use of bilateral lower extremity CUS in patients with PE.27
They found a prognostic value of diagnosing bilateral
distal DVT as well as proximal DVT during 2-year follow-up
using routine bilateral lower extremity CUS in patients
who were either symptomatic of DVT or at risk of having
DVT due to hospitalization or a diagnosis of PE. Moreover,
they suggested that among patients with DVT, with or
without PE, that the topography of the DVT may be clin-
ically more prognostically significant than the presence of
PE. In the present study, both the presence of DVT and
proximal DVT were independent predictors of adverse
outcome. The risk of post-thrombotic syndrome could
further support the use of surveillance CUS. Our previous
study showed that the presence of a high peak reflux
velocity in the proximal deep veins 2 years after initial
proximal DVT was a strong predictor of advanced symp-
toms of post-thrombotic syndrome at the 6-year follow-up
point.28
The relationship between clinical variables and
adverse outcome has been investigated by several groups.
Carson et al. found that heart failure and active cancer
Table 5 Multivariate analysis of potential risk factors for adverse outcome and development of the clinical score
Logistic regression coefficients Adjusted odds ratio (95% CI) p-value Point score
Active cancer 1.71 5.54 (2.36e13.00) <0.0001 þ2
Inadequate anticoagulation 1.35 3.84 (1.66e8.90) 0.002 þ1
Leg symptoms 1.31 3.70 (1.69e8.11) 0.001 þ1
Male gender 2.35 10.50 (4.10e26.89) <0.0001 þ2
Presence of DVT 1.60 4.97 (1.84e13.46) 0.002 þ1
Presence of proximal DVT 1.31 3.71 (1.74e7.94) 0.001 þ1
Previous history of DVT 2.13 8.39 (3.01e23.35) <0.0001 þ2
Total score 0e10
Table 6 Application of clinical score
Risk score No. of patients No. of patients with
adverse outcome (%)
0 32 0 (0)
1 34 1 (2.9)
2 31 2 (6.5)
3 46 4 (8.7)
4 23 3 (13.0)
5 19 11 (57.9)
6 8 5 (75.0)
7 7 3 (42.9)
8 1 1 (100)
9 1 1 (100)
10 1 1 (100)
230 T. Yamaki et al.were strong predictors of death during 1-year follow-up.29
Wicki et al. defined adverse outcomes as death, symp-
tomatic recurrent VTE, or major bleeding within a
3-month follow-up period, and found that factors associ-
ated with an adverse outcome in multivariate analysis
were cancer, heart failure, previous deep vein throm-
bosis, systolic blood pressure <100 mmHg, arterial
PaO2< 8 kPa, and presence of deep vein thrombosis on
ultrasound.11 They combined these independent risk
factors into an easily calculated risk score, and classified
patients as low-risk and high-risk. Using multivariate
analysis, we found that male gender, leg symptoms,
presence of DVT, presence of proximal DVT, active cancer
and previous history of DVT were independent predictors
for adverse outcome when recurrent VTE and fatal events
were considered. We also provided a clinical risk score
similar to that described by Wicki et al., and found that
the calculated score had a significant discriminatory
power, with an event rate of 6.0% in the low-risk group
versus 59.5% in the high-risk group.Risk_score






















Fig. 2 Receiver operating characteristic curve analysis for
risk score. Area under the ROC curve 0.84 (95% confidence
interval 0.78e0.89, pZ 0.0001).Our study had some potential limitations. First, there
was no precise information on the duration of oral anti-
coagulation, and we excluded duration of anticoagulation
from the risk analysis. The duration of anticoagulation
largely depends on the PE symptoms and the distribution
of DVT, although the study patients had received oral
anticoagulant therapy for more than 6 months. Second,
the follow-up period in our study was relatively long,
mainly due to the limited sample size with few clinical
events, which may represent a potential type II statistical
error. Nevertheless, our study clearly demonstrated the
significance of a clinical risk score for prediction of
adverse outcome within 1 year in patients with
symptomatic PE.
In conclusion, this study has demonstrated the clinical
significance of surveillance CUS in patients with a first
episode of PE. Multivariate analysis demonstrated that both
presence of DVT and presence of proximal DVT were inde-
pendent predictors of adverse events. Furthermore,
a simple risk score based on available variables was able to
identify PE patients at risk of an adverse outcome. Our
findings thus provide a routine diagnostic strategy for
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